Shopping Cart 0
Cart Subtotal
USD 0

Pruritus-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Pruritus-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus-Pipeline Review, H2 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 6, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).

The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Pruritus-Overview 7

Pruritus-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Pruritus-Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 19

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Pruritus-Companies Involved in Therapeutics Development 26

Albireo Pharma Inc 26

Allergan Plc 26

Amorepacific Corp 27

Asana BioSciences LLC 27

Cara Therapeutics Inc 28

Celgene Corp 28

Chugai Pharmaceutical Co Ltd 29

ELORAC Inc 29

GlaxoSmithKline Plc 30

Hydra Biosciences Inc 30

J Uriach Y Compania SA 31

NeuroCycle Therapeutics GmbH 31

Patagonia Pharmaceuticals LLC 32

Patara Pharma Inc 32

Phosphagenics Ltd 33

RDD Pharma Ltd 33

Sanwa Kagaku Kenkyusho Co Ltd 34

Shionogi & Co Ltd 34

Sienna Biopharmaceuticals Inc 35

Sumitomo Dainippon Pharma Co Ltd 35

Teikoku Pharma USA Inc 36

Tesaro Inc 36

Tioga Pharmaceuticals Inc 37

Toray Industries Inc 37

Vanda Pharmaceuticals Inc 38

Pruritus-Drug Profiles 39

A-4250-Drug Profile 39

apremilast-Drug Profile 43

asimadoline-Drug Profile 54

ASN-008-Drug Profile 56

B-244-Drug Profile 57

cromolyn sodium-Drug Profile 59

difelikefalin-Drug Profile 61

GSK-2330672-Drug Profile 71

lidocaine hydrochloride-Drug Profile 73

nalbuphine hydrochloride ER-Drug Profile 74

nalfurafine hydrochloride-Drug Profile 77

naloxone hydrochloride-Drug Profile 79

NCT-10004-Drug Profile 80

nemolizumab-Drug Profile 81

onabotulinumtoxinA-Drug Profile 83

PAC-14028-Drug Profile 88

PATN-02-Drug Profile 90

Peptides to Target TRPV1 for Pain and Itch-Drug Profile 91

phenylbutyrate-Drug Profile 92

PR-38-Drug Profile 93

RDD-1609-Drug Profile 94

rupatadine-Drug Profile 95

SCH-900978-Drug Profile 96

serlopitant-Drug Profile 97

SK-1405-Drug Profile 100

Small Molecule for Pruritus-Drug Profile 101

Small Molecule to Agonize KOR1 for Pruritus-Drug Profile 102

Small Molecules to Agonize CB2 for Pruritus-Drug Profile 103

Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus-Drug Profile 104

Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis-Drug Profile 105

SNA-120-Drug Profile 106

SNA-125-Drug Profile 109

TPU-010-Drug Profile 110

tradipitant-Drug Profile 111

VVZ-149-Drug Profile 113

Pruritus-Dormant Projects 115

Pruritus-Discontinued Products 117

Pruritus-Product Development Milestones 118

Featured News & Press Releases 118

Appendix 128

Methodology 128

Coverage 128

Secondary Research 128

Primary Research 128

Expert Panel Validation 128

Contact Us 128

Disclaimer 129


List Of Figure

List of Figures

Number of Products under Development for Pruritus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Pruritus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pruritus-Pipeline by Albireo Pharma Inc, H2 2017

Pruritus-Pipeline by Allergan Plc, H2 2017

Pruritus-Pipeline by Amorepacific Corp, H2 2017

Pruritus-Pipeline by Asana BioSciences LLC, H2 2017

Pruritus-Pipeline by Cara Therapeutics Inc, H2 2017

Pruritus-Pipeline by Celgene Corp, H2 2017

Pruritus-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Pruritus-Pipeline by ELORAC Inc, H2 2017

Pruritus-Pipeline by GlaxoSmithKline Plc, H2 2017

Pruritus-Pipeline by Hydra Biosciences Inc, H2 2017

Pruritus-Pipeline by J Uriach Y Compania SA, H2 2017

Pruritus-Pipeline by NeuroCycle Therapeutics GmbH, H2 2017

Pruritus-Pipeline by Patagonia Pharmaceuticals LLC, H2 2017

Pruritus-Pipeline by Patara Pharma Inc, H2 2017

Pruritus-Pipeline by Phosphagenics Ltd, H2 2017

Pruritus-Pipeline by RDD Pharma Ltd, H2 2017

Pruritus-Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017

Pruritus-Pipeline by Shionogi & Co Ltd, H2 2017

Pruritus-Pipeline by Sienna Biopharmaceuticals Inc, H2 2017

Pruritus-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Pruritus-Pipeline by Teikoku Pharma USA Inc, H2 2017

Pruritus-Pipeline by Tesaro Inc, H2 2017

Pruritus-Pipeline by Tioga Pharmaceuticals Inc, H2 2017

Pruritus-Pipeline by Toray Industries Inc, H2 2017

Pruritus-Pipeline by Vanda Pharmaceuticals Inc, H2 2017

Pruritus-Dormant Projects, H2 2017

Pruritus-Dormant Projects, H2 2017 (Contd..1), H2 2017

Pruritus-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Pruritus Therapeutic Products under Development, Key Players in Pruritus Therapeutics, Pruritus Pipeline Overview, Pruritus Pipeline, Pruritus Pipeline Assessment


Companies

Pruritus Therapeutic Products under Development, Key Players in Pruritus Therapeutics, Pruritus Pipeline Overview, Pruritus Pipeline, Pruritus Pipeline Assessment

Pruritus-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus-Pipeline Review, H2 2017, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 12, 6, 1 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).

The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 6

Global Markets Direct Report Coverage 6

Pruritus-Overview 7

Pruritus-Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 15

Pruritus-Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 19

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Pruritus-Companies Involved in Therapeutics Development 26

Albireo Pharma Inc 26

Allergan Plc 26

Amorepacific Corp 27

Asana BioSciences LLC 27

Cara Therapeutics Inc 28

Celgene Corp 28

Chugai Pharmaceutical Co Ltd 29

ELORAC Inc 29

GlaxoSmithKline Plc 30

Hydra Biosciences Inc 30

J Uriach Y Compania SA 31

NeuroCycle Therapeutics GmbH 31

Patagonia Pharmaceuticals LLC 32

Patara Pharma Inc 32

Phosphagenics Ltd 33

RDD Pharma Ltd 33

Sanwa Kagaku Kenkyusho Co Ltd 34

Shionogi & Co Ltd 34

Sienna Biopharmaceuticals Inc 35

Sumitomo Dainippon Pharma Co Ltd 35

Teikoku Pharma USA Inc 36

Tesaro Inc 36

Tioga Pharmaceuticals Inc 37

Toray Industries Inc 37

Vanda Pharmaceuticals Inc 38

Pruritus-Drug Profiles 39

A-4250-Drug Profile 39

apremilast-Drug Profile 43

asimadoline-Drug Profile 54

ASN-008-Drug Profile 56

B-244-Drug Profile 57

cromolyn sodium-Drug Profile 59

difelikefalin-Drug Profile 61

GSK-2330672-Drug Profile 71

lidocaine hydrochloride-Drug Profile 73

nalbuphine hydrochloride ER-Drug Profile 74

nalfurafine hydrochloride-Drug Profile 77

naloxone hydrochloride-Drug Profile 79

NCT-10004-Drug Profile 80

nemolizumab-Drug Profile 81

onabotulinumtoxinA-Drug Profile 83

PAC-14028-Drug Profile 88

PATN-02-Drug Profile 90

Peptides to Target TRPV1 for Pain and Itch-Drug Profile 91

phenylbutyrate-Drug Profile 92

PR-38-Drug Profile 93

RDD-1609-Drug Profile 94

rupatadine-Drug Profile 95

SCH-900978-Drug Profile 96

serlopitant-Drug Profile 97

SK-1405-Drug Profile 100

Small Molecule for Pruritus-Drug Profile 101

Small Molecule to Agonize KOR1 for Pruritus-Drug Profile 102

Small Molecules to Agonize CB2 for Pruritus-Drug Profile 103

Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus-Drug Profile 104

Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis-Drug Profile 105

SNA-120-Drug Profile 106

SNA-125-Drug Profile 109

TPU-010-Drug Profile 110

tradipitant-Drug Profile 111

VVZ-149-Drug Profile 113

Pruritus-Dormant Projects 115

Pruritus-Discontinued Products 117

Pruritus-Product Development Milestones 118

Featured News & Press Releases 118

Appendix 128

Methodology 128

Coverage 128

Secondary Research 128

Primary Research 128

Expert Panel Validation 128

Contact Us 128

Disclaimer 129


List Of Figure

List of Figures

Number of Products under Development for Pruritus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Pruritus, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pruritus-Pipeline by Albireo Pharma Inc, H2 2017

Pruritus-Pipeline by Allergan Plc, H2 2017

Pruritus-Pipeline by Amorepacific Corp, H2 2017

Pruritus-Pipeline by Asana BioSciences LLC, H2 2017

Pruritus-Pipeline by Cara Therapeutics Inc, H2 2017

Pruritus-Pipeline by Celgene Corp, H2 2017

Pruritus-Pipeline by Chugai Pharmaceutical Co Ltd, H2 2017

Pruritus-Pipeline by ELORAC Inc, H2 2017

Pruritus-Pipeline by GlaxoSmithKline Plc, H2 2017

Pruritus-Pipeline by Hydra Biosciences Inc, H2 2017

Pruritus-Pipeline by J Uriach Y Compania SA, H2 2017

Pruritus-Pipeline by NeuroCycle Therapeutics GmbH, H2 2017

Pruritus-Pipeline by Patagonia Pharmaceuticals LLC, H2 2017

Pruritus-Pipeline by Patara Pharma Inc, H2 2017

Pruritus-Pipeline by Phosphagenics Ltd, H2 2017

Pruritus-Pipeline by RDD Pharma Ltd, H2 2017

Pruritus-Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H2 2017

Pruritus-Pipeline by Shionogi & Co Ltd, H2 2017

Pruritus-Pipeline by Sienna Biopharmaceuticals Inc, H2 2017

Pruritus-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017

Pruritus-Pipeline by Teikoku Pharma USA Inc, H2 2017

Pruritus-Pipeline by Tesaro Inc, H2 2017

Pruritus-Pipeline by Tioga Pharmaceuticals Inc, H2 2017

Pruritus-Pipeline by Toray Industries Inc, H2 2017

Pruritus-Pipeline by Vanda Pharmaceuticals Inc, H2 2017

Pruritus-Dormant Projects, H2 2017

Pruritus-Dormant Projects, H2 2017 (Contd..1), H2 2017

Pruritus-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Pruritus Therapeutic Products under Development, Key Players in Pruritus Therapeutics, Pruritus Pipeline Overview, Pruritus Pipeline, Pruritus Pipeline Assessment


Companies

Pruritus Therapeutic Products under Development, Key Players in Pruritus Therapeutics, Pruritus Pipeline Overview, Pruritus Pipeline, Pruritus Pipeline Assessment